News

Targeted Oncology20h
AU-007 Appears Safe and Effective for Solid Tumors, Phase 2 Findings Show
Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety ...
Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting
Ten (10) patients have achieved an objective response (5 confirmed) when treated with MDNA11 alone or in combination with KEYTRUDA® (pembrolizumab) – all responders had advanced and/or metastatic canc ...
Metastatic Cutaneous Squamous Cell Cancer Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight
DelveInsight's "Metastatic Cutaneous Squamous Cell Cancer Market Insights, Epidemiology, and Market Forecast- 2032" report ...
PipelineReview.com15d
Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating AU-007 in Combination With Nivolumab for Second-Line Treatment of Melanoma
Preliminary Phase 2 data presented in November at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting showed that a combination of AU-007 and low-dose, subcutaneous aldesleukin is ...
CURE15d
AU-007 Combo Dosing Begins in Melanoma Phase 2 Trial With Opdivo
AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity ...
Clinical Trials Arena20d
First subject dosed in Amylyx’s Phase I trial of ALS therapy
Amylyx Pharmaceuticals has dosed the first subject in the Phase I LUMINA trial, investigating AMX0114, a potential treatment for ALS.
Cure Today1mon
First Patient Dosed in Trial of [212Pb]VMT01 for Metastatic Melanoma
[212Pb]VMT01 is being tested in combination with Opdivo in a phase 1/2a trial for melanoma patients with positive MC1R imaging scans. The FDA granted fast track designation to [212Pb]VMT01 for ...